Quick Answer
PLIANT THERAPEUTICS, INC. reported Total Revenue of $0.00 for fiscal year 2025.
PLIANT THERAPEUTICS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 -100.0% |
$1.58M -83.7% |
$9.69M +27.9% |
$7.57M -81.9% |
$41.82M -26.7% |
| Revenue (ASC 606) | $0.00 | $0.00 -100.0% |
$1.58M -83.7% |
$9.69M +27.9% |
$7.57M -81.9% |
$41.82M -26.7% |
| Net Income | -$149.34M +29.0% |
-$210.30M -30.4% |
-$161.34M -30.8% |
-$123.32M -26.8% |
-$97.26M -134.2% |
-$41.53M -6482.1% |
| Diluted EPS | -$2.43 +30.0% |
-$3.47 -26.2% |
-$2.75 +6.5% |
-$2.94 -8.5% |
-$2.71 -39.0% |
-$1.95 +53.8% |
| Total Assets | $225.23M -43.3% |
$396.95M -22.5% |
$512.15M +46.1% |
$350.61M +58.5% |
$221.22M -25.1% |
$295.53M +148.2% |
| Cash and Equivalents | $45.45M -36.2% |
$71.19M +12.6% |
$63.23M +87.7% |
$33.69M -34.8% |
$51.66M +1.5% |
$50.88M -40.7% |
| Long-Term Debt | $0.00 -100.0% |
$30.21M +200.5% |
$10.05M +1.3% |
$9.93M | $0.00 | — |
| Stockholders Equity | $181.21M -40.4% |
$304.08M -35.8% |
$473.58M +51.1% |
$313.34M +57.4% |
$199.06M -29.7% |
$283.06M +471.0% |
| R&D Expense | $109.16M -35.5% |
$169.31M +32.5% |
$127.80M +31.8% |
$96.94M +25.0% |
$77.55M +17.2% |
$66.19M +39.8% |
| Operating Income | -$156.37M +31.5% |
-$228.37M -24.0% |
-$184.15M -44.8% |
-$127.20M -30.4% |
-$97.53M -134.2% |
-$41.65M -3283.0% |
| Shares Outstanding | 61.45M +1.0% |
60.86M +1.6% |
59.92M +22.4% |
48.94M +35.6% |
36.08M +1.5% |
35.55M +1825.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2024 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2024 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$26.30M | +54.5% | +39.3% |
| Diluted EPS | September 30, 2025 | -$0.43 | +54.7% | +39.4% |
| Total Assets | September 30, 2025 | $276.60M | -37.9% | -7.7% |
| Cash and Equivalents | September 30, 2025 | $93.73M | +17.7% | +8.0% |
| Long-Term Debt | September 30, 2025 | $30.44M | +1.0% | +0.3% |
| Stockholders Equity | September 30, 2025 | $200.31M | -42.1% | -9.0% |
| R&D Expense | September 30, 2025 | $17.94M | -62.4% | -44.3% |
| Operating Income | September 30, 2025 | -$28.27M | +54.4% | +38.0% |
| Shares Outstanding | September 30, 2025 | 61.45M | +1.0% | +0.1% |
- PLIANT THERAPEUTICS, INC. reported Total Revenue of $0.00 for fiscal year 2025.
- PLIANT THERAPEUTICS, INC. reported Revenue (ASC 606) of $0.00 for fiscal year 2025.
- PLIANT THERAPEUTICS, INC. reported Net Income of -$149.34 million for fiscal year 2025.
- PLIANT THERAPEUTICS, INC. showed an increase of +29.0% in Net Income compared to the prior fiscal year.
- PLIANT THERAPEUTICS, INC. reported Diluted EPS of $2.43 per share (loss) for fiscal year 2025.
- PLIANT THERAPEUTICS, INC. showed an increase of +30.0% in Diluted EPS compared to the prior fiscal year.
- PLIANT THERAPEUTICS, INC. reported Total Assets of $225.23 million for fiscal year 2025.
- PLIANT THERAPEUTICS, INC. showed a decrease of -43.3% in Total Assets compared to the prior fiscal year.
- PLIANT THERAPEUTICS, INC. reported Cash and Equivalents of $45.45 million for fiscal year 2025.
- PLIANT THERAPEUTICS, INC. showed a decrease of -36.2% in Cash and Equivalents compared to the prior fiscal year.
- PLIANT THERAPEUTICS, INC. reported Long-Term Debt of $0.00 for fiscal year 2025.
- PLIANT THERAPEUTICS, INC. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- PLIANT THERAPEUTICS, INC. reported Stockholders Equity of $181.21 million for fiscal year 2025.
- PLIANT THERAPEUTICS, INC. showed a decrease of -40.4% in Stockholders Equity compared to the prior fiscal year.
- PLIANT THERAPEUTICS, INC. reported R&D Expense of $109.16 million for fiscal year 2025.
- PLIANT THERAPEUTICS, INC. showed a decrease of -35.5% in R&D Expense compared to the prior fiscal year.
- PLIANT THERAPEUTICS, INC. reported Operating Income of -$156.37 million for fiscal year 2025.
- PLIANT THERAPEUTICS, INC. showed an increase of +31.5% in Operating Income compared to the prior fiscal year.
- PLIANT THERAPEUTICS, INC. reported Shares Outstanding of 61.45 million shares for fiscal year 2025.
- PLIANT THERAPEUTICS, INC. showed an increase of +1.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: